As it was preparing to divide itself in two last summer, Ironwood pink-slipped 40 staffers. But it turns out those layoffs were only the beginning.
A pair of Korean companies have teamed up to buy stem cell manufacturing facilities and other assets of a failed U.S. biotech.
Drug wholesaler McKesson was lashed in an FDA warning letter for shipments in which opioids had been replaced by OTC drugs.
Mylan has set its list price for its Advair copy at a 70% discount to the brand. But the move may not be as dramatic as it seems.
Sanofi taps its chief medical officer to also become its first chief digital officer, combining the two roles inside the company.
In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.
Bayer and Geisinger aim to put contraception front and center in women's health visits, starting even before a patient sets foot in the clinic.
BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
Catalyst is unfazed by a letter from Sen. Bernie Sanders demanding that it justify the cost of its rare-disease drug Firdapse, confirmed at $300K after…
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.